Vicagrel is an oral antiplatelet agent designed to prevent thrombotic cardiovascular events by selectively inhibiting the P2Y12 receptor to block platelet aggregation. It is indicated for the secondary… Read more
![Chemical structure of (S)-2-(2-Acetoxy-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-2-(2-chlorophenyl-3,4,5,6-d4)acetic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FS-2-2-Acetoxy-67-dihydrothieno32-cpyridin-54H-yl-2-2-chlorophenyl-3456-d4acetic-Acid.png&w=3840&q=75)





Vicagrel is an oral antiplatelet agent designed to prevent thrombotic cardiovascular events by selectively inhibiting the P2Y12 receptor to block platelet aggregation. It is indicated for the secondary prevention of stroke and myocardial infarction in patients diagnosed with acute coronary syndrome or stable angina. The pharmaceutical reference standards, metabolites, and synthetic impurities in this category are essential for rigorous analytical testing and method validation throughout the drug development lifecycle. Laboratories rely on these high-quality compounds, including stable isotope labelled analogues like Vicagrel-d4 and its derivatives, to perform accurate impurity profiling and quantitative analysis. By utilizing these materials for purity assessment and quality control, researchers can ensure compliance with regulatory standards and maintain the precision of pharmacokinetic studies involving this antiplatelet therapy.